M&A Deal Summary

Vaxil Bio Acquires Short Wave

On October 14, 2021, Vaxil Bio acquired life science company Short Wave

Acquisition Highlights
  • This is Vaxil Bio’s 1st transaction in the Life Science sector.
  • This is Vaxil Bio’s 1st transaction in Israel.

M&A Deal Summary
Date 2021-10-14
Target Short Wave
Sector Life Science
Buyer(s) Vaxil Bio
Deal Type Add-on Acquisition

Target

Short Wave

Israel
Short Wave is an Israeli-based pre-clinical stage biotech company focused on the development of IP-protected formulations and delivery methods of psychedelics-based medicine to treat mental illness, chronic pain, and neurodegenerative diseases. Short Wave is based in Israel.

Search 193,103 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Vaxil Bio

Toronto, Ontario, Canada

website

Category Company
Founded 2006
Sector Life Science
DESCRIPTION

Vaxil Bio is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Vaxil Bio's product ImMucin successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. Vaxil Bio was founded in 2006 and is based in Toronto, Ontario.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Israel) 1 of 1
Year (2021) 1 of 1
Mergr

Product

Company

Legal